2025
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment
Alhajahjeh A, Stahl M, Kim T, Kewan T, Stempel J, Zeidan A, Bewersdorf J. Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-22. PMID: 40122075, DOI: 10.1080/14737140.2025.2483855.Peer-Reviewed Original ResearchMyeloid-derived suppressor cellsAcute myeloid leukemiaMyelodysplastic syndromeSuppressor cellsTumor microenvironmentMyeloid leukemiaEffects of myeloid-derived suppressor cellsTargets myeloid-derived suppressor cellsLeukemic stem cell survivalRisk of leukemia relapseMDSC-targeted therapiesMDSC-mediated immunosuppressionBone marrow nicheStem cell survivalCytokine-mediated pathwaysLeukemia relapseMyeloid diseasesImprove patient outcomesMarrow nichePost-transplantationPreclinical modelsImmunosuppressive propertiesImmunosuppressive componentsFunctional reprogrammingImmune evasion
2016
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors
Stahl M, Gedrich R, Peck R, LaVallee T, Eder JP. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. Immunotherapy 2016, 8: 767-774. PMID: 27349976, DOI: 10.2217/imt-2016-0040.Peer-Reviewed Original ResearchConceptsMyeloid-derived suppressor cellsInnate immune cellsCheckpoint inhibitorsSuppressor cellsImmune cellsMast cellsImmune checkpoint inhibitorsAntitumor immune responseImmune cell numbersReceptor tyrosine kinase KITDurable responsesMelanoma patientsClinical benefitTyrosine kinase KITCancer patientsPreclinical dataPoor survivalImmune responseSuppressive componentsImmune systemKIT inhibitorsTumor microenvironmentAntitumor activityKinase KITRecent evidence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply